Seeing Is Believing
Currently out of the existing stock ratings of Sumant Kulkarni, 143 are a BUY (86.14%), 23 are a HOLD (13.86%).
Analyst Sumant Kulkarni, currently employed at CANACCORD, carries an average stock price target met ratio of 33.34% that have a potential upside of 25.03% achieved within 152 days.
Sumant Kulkarni’s has documented 329 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SAGE, Sage Therapeutic at 17-Jun-2025.
Analyst best performing recommendations are on CRTX (CORTEXYME).
The best stock recommendation documented was for CRTX (CORTEXYME) at 6/3/2019. The price target of $42 was fulfilled within 15 days with a profit of $17.87 (74.06%) receiving and performance score of 49.37.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$37
$14.88 (67.27%)
$42
6 days ago
(26-Jun-2025)
9/16 (56.25%)
$14.79 (66.59%)
238
Buy
$32
$9.88 (44.67%)
$32
6 days ago
(26-Jun-2025)
7/23 (30.43%)
$9.79 (44.08%)
118
Buy
$30
$7.88 (35.62%)
$30
6 days ago
(26-Jun-2025)
0/9 (0%)
$7.79 (35.07%)
Hold
$22
$-0.12 (-0.54%)
$19
6 days ago
(26-Jun-2025)
15/16 (93.75%)
$-0.21 (-0.95%)
94
Buy
$30
$7.88 (35.62%)
$25
26 days ago
(06-Jun-2025)
5/9 (55.56%)
$8.02 (36.49%)
26
Which stock is Sumant Kulkarni is most bullish on?
Which stock is Sumant Kulkarni is most reserved on?
What Year was the first public recommendation made by Sumant Kulkarni?